IP Library Granted Patent US 10,987,385
Granted Patent B2
US 10,987,385 · App. 16/109,413 · Granted Apr 27, 2021

Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them

Inventor: Thomas Julius Borody (Five Dock, AU)
Assignee: Finch Therapeutics Holdings LLC
A61K35/74A61K9/4891A61K35/24A61K35/742A61M5/142A61P1/12C12N1/00A61B10/0038A61K9/4875A61K2035/115A61M31/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,987,385
App. No.
16/109,413
Granted
Apr 27, 2021
Kind
B2
Abstract

In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated travelers diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. The invention also provides devices for delivering a fecal material to a patient.

Claims (27)

1. A method of treating seizures in a patient in need thereof, the method comprising:

administering to said patient a pharmaceutical preparation comprising a substantially entire microbiota of a stool and a cryoprotectant.

2. The method of claim 1 , wherein said substantially entire microbiota of said stool is free of rough particulate matter.

3. The method of claim 1 , wherein said cryoprotectant is trehalose.

4. The method of claim 1 , wherein said pharmaceutical preparation further comprises an antioxidant.

5. The method of claim 1 , wherein said pharmaceutical preparation further comprises cysteine.

6. The method of claim 1 , wherein said pharmaceutical preparation comprises glycerol, skim milk, erythritol, arabitol, sorbitol, glucose, or fructose.

7. The method of claim 1 , wherein said pharmaceutical preparation is encapsulated.

8. The method of claim 1 , wherein said seizure is a grand mal seizure.

9. The method of claim 1 , wherein said seizure is a petit mal seizure.

10. A method of treating seizures in a patient in need thereof, the method comprising: administering to said patient a filtrate comprising a substantially entire microbiota of a stool.

11. The method of claim 10 , wherein said filtrate is free of rough particulate matter of said stool.

12. The method of claim 10 , wherein said filtrate is lyophilized.

13. The method of claim 10 , wherein said filtrate further comprises a cryoprotectant.

14. The method of claim 10 , wherein said filtrate is encapsulated into a carrier.

15. The method of claim 14 , wherein said encapsulated filtrate is in a graded release capsule.

16. The method of claim 10 , wherein said seizure is a grand mal seizure.

17. The method of claim 10 , wherein said seizure is a petit mal seizure.

18. A method of treating seizures in a patient in need thereof, the method comprising: administering to said patient a pharmaceutical preparation comprising uncultured fecal bacteria from a donor stool.

19. The method of claim 18 , wherein said pharmaceutical preparation is free of rough particulate matter of said stool.

20. The method of claim 18 , wherein said pharmaceutical preparation does not contain Bacteroides.

21. The method of claim 18 , wherein said pharmaceutical preparation is lyophilized.

22. The method of claim 18 , wherein said pharmaceutical preparation further comprises a cryoprotectant.

23. The method of claim 18 , wherein said pharmaceutical preparation is encapsulated into a carrier.

24. The method of claim 23 , wherein said encapsulated pharmaceutical composition is in a graded release capsule.

25. The method of claim 18 , wherein said seizure is a grand mal seizure.

26. The method of claim 18 , wherein said seizure is a petit mal seizure.

Assignments (5)
CHANGE OF NAME Recorded Dec 31, 2020
From: CRESTOVO HOLDINGS LLC
To: FINCH THERAPEUTICS HOLDINGS LLC
Reel/Frame 054883/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2020
From: BORODY, THOMAS
To: CRESTOVO LLC
Reel/Frame 054608/0061 →
CONFIRMATORY ASSIGNMENT Recorded Dec 10, 2020
From: CRESTOVO LLC
To: CRESTOVO HOLDINGS LLC
Reel/Frame 054677/0086 →
RELEASE OF SECURITY INTEREST Recorded Sep 5, 2019
From: CRESTOVO INVESTOR LLC; M3 VENTURES - FINCH II LLC; AVENIR FINCH INVESTORS LLC; FLIGHT PARTNERS MANAGEMENT LLC; NATIONAL PHILANTHROPIC TRUST; 91313 INVESTMENT HOLDING I LLC; SILAS HOLDING I LLC; BEE HILL HOLDINGS LLC; GORMAN, DYLAN; CHOI, KENNETH S.
To: CRESTOVO HOLDINGS LLC
Reel/Frame 050274/0530 →
SECURITY INTEREST Recorded Mar 7, 2019
From: CRESTOVO HOLDINGS LLC
To: CRESTOVO INVESTOR LLC; M3 VENTURES - FINCH II LLC; AVENIR FINCH INVESTORS, LLC; FLIGHT PARTNERS MANAGEMENT LLC; NATIONAL PHILANTHROPIC TRUST; 91313 INVESTMENT HOLDINGS LLC; SILAS HOLDINGS LLC; BEE HILL HOLDINGS LLC; GORMAN, DYLAN; CHOI, KENNETH S.
Reel/Frame 050111/0166 →
Priority Claims (1)
AU 2010903474 · Aug 4, 2010 · national
Continuity (10)
Continuation 15975456 · May 9, 2018
Continuation 15950939 · Apr 11, 2018
Continuation 15782519 · Oct 12, 2017
Continuation 15093679 · Apr 7, 2016
Continuation 13813915
Provisional Application 61494363 · Jun 7, 2011
Provisional Application 61483487 · May 6, 2011
Provisional Application 61451087 · Mar 9, 2011
Provisional Application 61450099 · Mar 7, 2011
Related Publication 20190046589A1 · Feb 14, 2019
Cited By (1)
US 12,409,085